Partners Capital Investment Group Holdings LLC raised its position in shares of Johnson & Johnson (NYSE:JNJ) by 7.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 155,349 shares of the company’s stock after purchasing an additional 10,378 shares during the period. Johnson & Johnson makes up approximately 3.9% of Partners Capital Investment Group Holdings LLC’s investment portfolio, making the stock its 11th biggest position. Partners Capital Investment Group Holdings LLC’s holdings in Johnson & Johnson were worth $19,349,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Lau Associates LLC raised its position in Johnson & Johnson by 12.8% during the first quarter. Lau Associates LLC now owns 46,878 shares of the company’s stock valued at $5,839,000 after purchasing an additional 5,335 shares in the last quarter. Jackson Grant Investment Advisers Inc. increased its holdings in shares of Johnson & Johnson by 7.3% during the fourth quarter. Jackson Grant Investment Advisers Inc. now owns 14,124 shares of the company’s stock worth $1,627,000 after buying an additional 957 shares in the last quarter. Burke & Herbert Bank & Trust Co. increased its holdings in shares of Johnson & Johnson by 2.6% during the first quarter. Burke & Herbert Bank & Trust Co. now owns 47,330 shares of the company’s stock worth $5,895,000 after buying an additional 1,218 shares in the last quarter. Paradigm Financial Advisors LLC increased its holdings in shares of Johnson & Johnson by 17.1% during the first quarter. Paradigm Financial Advisors LLC now owns 2,640 shares of the company’s stock worth $328,000 after buying an additional 386 shares in the last quarter. Finally, Peachtree Investment Advisors Inc. increased its holdings in shares of Johnson & Johnson by 0.7% during the first quarter. Peachtree Investment Advisors Inc. now owns 22,138 shares of the company’s stock worth $2,757,000 after buying an additional 160 shares in the last quarter. Institutional investors and hedge funds own 66.00% of the company’s stock.

Shares of Johnson & Johnson (JNJ) traded down 0.92% during mid-day trading on Friday, reaching $130.98. 4,854,414 shares of the company’s stock were exchanged. Johnson & Johnson has a one year low of $109.32 and a one year high of $137.08. The company has a 50 day moving average price of $132.48 and a 200-day moving average price of $128.74. The stock has a market cap of $351.55 billion, a PE ratio of 22.16 and a beta of 0.79.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.79 by $0.04. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The firm had revenue of $18.84 billion for the quarter, compared to analysts’ expectations of $18.94 billion. During the same quarter in the previous year, the company earned $1.74 earnings per share. The company’s revenue for the quarter was up 1.9% compared to the same quarter last year. On average, analysts predict that Johnson & Johnson will post $7.18 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.57%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s payout ratio is 56.76%.

Several research analysts have recently issued reports on JNJ shares. Royal Bank Of Canada reiterated a “buy” rating and set a $128.00 price target on shares of Johnson & Johnson in a report on Thursday, June 15th. BMO Capital Markets reiterated a “buy” rating and set a $132.00 price target on shares of Johnson & Johnson in a report on Friday, June 2nd. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $132.33 price target for the company in a report on Monday, May 29th. Cowen and Company reiterated a “buy” rating and set a $143.00 price target (up from $138.00) on shares of Johnson & Johnson in a report on Friday, May 19th. Finally, UBS AG reiterated a “buy” rating and set a $136.00 price target on shares of Johnson & Johnson in a report on Monday, May 15th. Three analysts have rated the stock with a sell rating, nine have given a hold rating and ten have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $134.60.

COPYRIGHT VIOLATION NOTICE: This news story was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright and trademark laws. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/09/10/johnson-johnson-jnj-shares-bought-by-partners-capital-investment-group-holdings-llc.html.

In other Johnson & Johnson news, VP Paulus Stoffels sold 102,692 shares of the business’s stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $133.14, for a total value of $13,672,412.88. Following the transaction, the vice president now owns 230,342 shares in the company, valued at $30,667,733.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Dominic J. Caruso sold 82,591 shares of the business’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the completion of the transaction, the vice president now owns 226,693 shares in the company, valued at approximately $30,993,466.96. The disclosure for this sale can be found here. 0.19% of the stock is currently owned by insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.